This 2021 Loser Stock Could Be 2022's Biggest Winner

Motley Fool2021-12-23

Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

162

Report

Comment（20）

Ligercub
·2021-12-23
Lousy stocks
Reply
Like
Report
SanWangtikup
·2021-12-23
👍
Reply
Like
Report
koolgal
·2021-12-23
Teladoc, a necessity borne out of Covid19. A time when lockdowns were everywhere. But now as the economy is slowly opening, its demand is not as high as before. Still it has great potential to grow as it is so easy to see a doctor virtually. Hopefully 2022 will be a better year for Teladoc!
Reply
17
Report
Fold Replies
- Liana123:
  👍
  2021-12-25
  Reply
  Report
- breAkdaWn:
  telephone a doctor is available everywhere, the charges to the patients are same, without the physical examination. good for doctors to make easy money!
  2021-12-24
  Reply
  Report
- koolgal:
  It is on my watch list.
  2021-12-24
  Reply
  Report
View more 2 comments
hmmwvms
·2021-12-23
Get me the doc
Reply
1
Report
james_l
·2021-12-23
Teladoc rose partly as a covid momentum play. Without covid it needs to be looked where exactly it is suppose to be at.
Reply
3
Report
Fold Replies
- SeLby:
  Ok
  2021-12-23
  Reply
  Report
Bennylai
·2021-12-23
[Strong]
Reply
2
Report
Ramlacs
·2021-12-23
Good,,,thanks
Reply
2
Report
Ramlacs
·2021-12-23
Good!!!
Reply
1
Report
Popo123
·2021-12-23
Same sentiments
Reply
1
Report
Tyanak
·2021-12-23
👍🏼
Reply
Like
Report
OPP
·2021-12-23
Like please
Reply
1
Report
ALAL
·2021-12-23
Yes
Reply
1
Report
lzh77
·2021-12-23
Like please
Reply
5
Report
Fionfion82
·2021-12-23
Ok
Reply
2
Report
moliya
·2021-12-23
Losers are new winners and winners are losers......ha ha ha hahah
Reply
2
Report
ZB90
·2021-12-23
@
Reply
3
Report
Aaronnz
·2021-12-23
Hi
Reply
1
Report
mildred
·2021-12-23
[財迷]
Reply
1
Report
Fold Replies
- Ahleepapa:
  Gd
  2021-12-23
  Reply
  Report
Simranjeet
·2021-12-23
Hmmmm
Reply
3
Report
Blokk
·2021-12-23
Interesting
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2193519088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-12-23 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2193519088","market":"us","top_or_hot":-1,"title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","media":"Motley Fool","content":"<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","article_id":"2193519088","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","pubTimestamp":1640226997,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4504":"桥水持仓"},"translate_title":"这只2021年的失败者股票可能是2022年最大的赢家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":0.9},"content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9000420760,"gmtCreate":1640268396206,"gmtModify":1676533513346,"author":{"id":"3582065364125353","authorId":"3582065364125353","name":"Ligercub","avatar":"https://static.tigerbbs.com/83d5fda0835cef58a6bd5f7767d211b9","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Lousy stocks","listText":"Lousy stocks","text":"Lousy stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000420760","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000492696,"gmtCreate":1640255054341,"gmtModify":1676533512135,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000492696","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":698003577,"gmtCreate":1640253669510,"gmtModify":1676532433568,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1},"htmlText":"Teladoc, a necessity borne out of Covid19.&nbsp; A time when lockdowns were everywhere.&nbsp; But now as the economy is slowly opening, its demand is not as high as before. Still it has great potential to grow as it is so easy to see a doctor virtually.&nbsp; Hopefully&nbsp;2022 will be a better year for Teladoc!&nbsp;","listText":"Teladoc, a necessity borne out of Covid19.&nbsp; A time when lockdowns were everywhere.&nbsp; But now as the economy is slowly opening, its demand is not as high as before. Still it has great potential to grow as it is so easy to see a doctor virtually.&nbsp; Hopefully&nbsp;2022 will be a better year for Teladoc!&nbsp;","text":"Teladoc, a necessity borne out of Covid19. A time when lockdowns were everywhere. But now as the economy is slowly opening, its demand is not as high as before. Still it has great potential to grow as it is so easy to see a doctor virtually. Hopefully 2022 will be a better year for Teladoc!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":17,"commentSize":18,"repostSize":0,"link":"https://ttm.financial/post/698003577","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100032141,"gmtCreate":1640446465145,"gmtModify":1663241549732,"authorId":4102640698656550,"author":{"id":4102640698656550,"authorId":4102640698656550,"name":"Liana123","avatar":"https://static.tigerbbs.com/5beb28fd2b861c760f9ac5a5d8f52013","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698003577,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":7092531,"gmtCreate":1640294097405,"gmtModify":1663239122050,"authorId":3569809505691000,"author":{"id":3569809505691000,"authorId":3569809505691000,"name":"breAkdaWn","avatar":"https://community-static.tradeup.com/news/4c3676c14de9bfcd6f45bcf7ba4ddb6c","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.11","exceedPercentage":"80.02%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698003577,"type":1,"supId":0,"prevId":0,"content":"<p>telephone a doctor is available everywhere, the charges to the patients are same, without the physical examination. good for doctors to make easy money!</p>","text":"<p>telephone a doctor is available everywhere, the charges to the patients are same, without the physical examination. good for doctors to make easy money!</p>","html":"<p>telephone a doctor is available everywhere, the charges to the patients are same, without the physical examination. good for doctors to make easy money!</p>"},{"id":7092662,"gmtCreate":1640295693507,"gmtModify":1663239122032,"authorId":3559581955535845,"author":{"id":3559581955535845,"authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.30","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":698003577,"type":1,"supId":7089190,"prevId":0,"content":"It is on my watch list.","text":"It is on my watch list.","html":"It is on my watch list."},{"id":7092661,"gmtCreate":1640295674562,"gmtModify":1663239121535,"authorId":3559581955535845,"author":{"id":3559581955535845,"authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.30","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":698003577,"type":1,"supId":7089857,"prevId":0,"content":"Thanks for sharing.","text":"Thanks for sharing.","html":"Thanks for sharing."},{"id":7091990,"gmtCreate":1640277002776,"gmtModify":1663239120743,"authorId":4094793324288350,"author":{"id":4094793324288350,"authorId":4094793324288350,"name":"Urbanpro","avatar":"https://static.itradeup.com/news/a746e7a822edfd5383428826b62a463a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698003577,"type":1,"supId":0,"prevId":0,"content":"wow ...you are so very the active on tiger, merry Xmas","text":"wow ...you are so very the active on tiger, merry Xmas","html":"wow ...you are so very the active on tiger, merry Xmas"}],"langContent":"CN"},{"id":691777062,"gmtCreate":1640253052515,"gmtModify":1676532433477,"author":{"id":"3578570760040163","authorId":"3578570760040163","name":"hmmwvms","avatar":"https://static.tigerbbs.com/a906b2444a1aca7cd161a6e1ee03687e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Get me the doc","listText":"Get me the doc","text":"Get me the doc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691777062","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691755127,"gmtCreate":1640250216796,"gmtModify":1676532432798,"author":{"id":"3563436875655076","authorId":"3563436875655076","name":"james_l","avatar":"https://static.tigerbbs.com/7960ea5c640db331ff2de0da32f6a611","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Teladoc rose partly as a covid momentum play. Without covid it needs to be looked where exactly it is suppose to be at.","listText":"Teladoc rose partly as a covid momentum play. Without covid it needs to be looked where exactly it is suppose to be at.","text":"Teladoc rose partly as a covid momentum play. Without covid it needs to be looked where exactly it is suppose to be at.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/691755127","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100022101,"gmtCreate":1640252703333,"gmtModify":1663241498232,"authorId":3583197598199652,"author":{"id":3583197598199652,"authorId":3583197598199652,"name":"SeLby","avatar":"https://static.tigerbbs.com/ad7f9d9a13a537bcb9c5ad29a65aa424","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691755127,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":9000400207,"gmtCreate":1640249579346,"gmtModify":1676533511792,"author":{"id":"4088771619340210","authorId":"4088771619340210","name":"Bennylai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1},"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000400207","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":691750322,"gmtCreate":1640248851878,"gmtModify":1676532432464,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Good,,,thanks&nbsp;","listText":"Good,,,thanks&nbsp;","text":"Good,,,thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691750322","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691727717,"gmtCreate":1640248829970,"gmtModify":1676532432449,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Good!!!","listText":"Good!!!","text":"Good!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691727717","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9000574529,"gmtCreate":1640248421489,"gmtModify":1676533511744,"author":{"id":"4102506918623310","authorId":"4102506918623310","name":"Popo123","avatar":"https://static.tigerbbs.com/486873c14795c94fa86e194c8bec2cd7","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Same sentiments&nbsp;","listText":"Same sentiments&nbsp;","text":"Same sentiments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000574529","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000542267,"gmtCreate":1640244782557,"gmtModify":1676533511309,"author":{"id":"4099464847810740","authorId":"4099464847810740","name":"Tyanak","avatar":"https://static.tigerbbs.com/06395489130b165c03280007e704e978","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"👍🏼","listText":"👍🏼","text":"👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000542267","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000548901,"gmtCreate":1640244180616,"gmtModify":1676533511251,"author":{"id":"3587030474832187","authorId":"3587030474832187","name":"OPP","avatar":"https://static.tigerbbs.com/9d08e95ca3ed272bd428558fc0aae8bc","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000548901","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000540072,"gmtCreate":1640243107741,"gmtModify":1676533511156,"author":{"id":"3573967796529092","authorId":"3573967796529092","name":"ALAL","avatar":"https://static.tigerbbs.com/875b16da8a8772902d1aaf69f6c0d98a","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000540072","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":691738435,"gmtCreate":1640240747428,"gmtModify":1676532430997,"author":{"id":"3581654499912172","authorId":"3581654499912172","name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691738435","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9000527602,"gmtCreate":1640239747340,"gmtModify":1676533510870,"author":{"id":"3567652695695694","authorId":"3567652695695694","name":"Fionfion82","avatar":"https://static.tigerbbs.com/22ca6345985b52ec868cac92aafafdc1","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000527602","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":691795602,"gmtCreate":1640239350711,"gmtModify":1676532430813,"author":{"id":"3552850525395609","authorId":"3552850525395609","name":"moliya","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":3,"crmLevelSwitch":1},"htmlText":"Losers are new winners and winners are losers......ha ha ha hahah","listText":"Losers are new winners and winners are losers......ha ha ha hahah","text":"Losers are new winners and winners are losers......ha ha ha hahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691795602","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9000524957,"gmtCreate":1640239313509,"gmtModify":1676533510828,"author":{"id":"4097132802055230","authorId":"4097132802055230","name":"ZB90","avatar":"https://static.tigerbbs.com/4f5eba8367be5f6cb5d2fe550f01ad81","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"@","listText":"@","text":"@","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000524957","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000524099,"gmtCreate":1640239306502,"gmtModify":1676533510820,"author":{"id":"3583727724427055","authorId":"3583727724427055","name":"Aaronnz","avatar":"https://static.tigerbbs.com/081382b8819d97b743c11f71bcb95f0b","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000524099","repostId":2193519088,"repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":691483772,"gmtCreate":1640227657791,"gmtModify":1676532428457,"author":{"id":"3574387804838851","authorId":"3574387804838851","name":"mildred","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"[財迷]&nbsp;","listText":"[財迷]&nbsp;","text":"[財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/691483772","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7086172,"gmtCreate":1640228971676,"gmtModify":1663239092248,"authorId":3585038405943602,"author":{"id":3585038405943602,"authorId":3585038405943602,"name":"Ahleepapa","avatar":"https://static.tigerbbs.com/dcc1fea9c38112b58c68a2d96017330b","vip":1,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691483772,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"}],"langContent":"CN"},{"id":691417337,"gmtCreate":1640227255488,"gmtModify":1676532428275,"author":{"id":"3573354336738769","authorId":"3573354336738769","name":"Simranjeet","avatar":"https://static.tigerbbs.com/30dfcd8b012219a117929a3874586c3e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691417337","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691416051,"gmtCreate":1640227024544,"gmtModify":1676532428174,"author":{"id":"3585967633447217","authorId":"3585967633447217","name":"Blokk","avatar":"https://static.tigerbbs.com/41113e8716dd467d6afdee4030a0d7f2","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691416051","repostId":2193519088,"repostType":4,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","BK4567":"ESG概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":162,"commentSize":20,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}